Discovery/R&D

  1. Lipid Nanoparticle Gene Coding With SalioGen Therapeutics' Ray Tabibiazar, M.D. 3/14/2022

    This episode of the Business of Biotech is fire. In fact, it's an interview with SalioGen Therapeutics Chairman and CEO Ray Tabibiazar, M.D.,, whose last name \_literally translates\_ to "Dr. Fire." Learn how he got that name, what's shaped his technology-agnostic philosophy on therapeutic development, the advantages of a genome engineering technology that leverages proprietary mammal-derived enzymes, rather than viruses, and how SalioGen is possibly carrying forth a pipeline that's 15 candidates deep and addressing eye, liver, heart, lung, bone marrow, and kidney diseases.

  2. The AAV Vector Challenge With Selecta's Dr. Carsten Brunn 1/12/2021

    The Business of Biotech kicks off our Cell & Gene Miniseries with Dr. Carsten Brunn, President & CEO at Selecta Biosciences. Guest host Erin Harris, chief editor at cellandgene.com, joins us for a discussion on Selecta's ImmTOR platform and how the company is addressing the immunogenicity of adeno-associated virus (AAV) vectors challenge faced by gene therapy companies.

  3. Accelerating ADCs with Mythic Therapeutics' Brian Fiske, Ph.D. 5/26/2024

    Mythic Therapeutics Chief Scientific Officer and Co-Founder Brian Fiske, Ph.D. broke some unwritten protocol with his rapid and multifaceted transition from academia to industry. He calls his many, and sometimes concurrent, early experiences as an MIT Ph.D. student, a Flagship Ventures Fellow, a Bain consultant, a hospital researcher, and a biopharma consultant indicative of a young man who didn't want to make decisions.

  4. Cannabinoid And Psychedelic Combinations With Incannex Healthcare's Joel Latham 9/19/2025

    On this week's Business Of Biotech episode, Joel Latham, President and CEO at Incannex Healthcare, talks about developing cannabinoid and psychedelic combination therapies for conditions as diverse as sleep apnea, rheumatoid arthritis, and generalized anxiety disorder.

  5. Genetic Testing & Neurodegenerative Disorders With AviadoBio's Lisa Deschamps 8/29/2022

    Lisa Deschamps' story is one of determination and fortitude. She got her start in the life sciences where it begins and ends for many — "carrying the bag" in big pharma sales — then proceeded to crush the odds on her way to the C-suite at Novartis. Today, she's CEO at AviadoBio, a disruptive gene therapy startup prepping an intra-thalamic Frontotemporal Dementia candidate for the clinic with a heavy Series A in its hip pocket. On this episode of the Business of Biotech we get to know Lisa, her company and its therapeutic approach, her advocacy for genetic testing, and how she's applying her determination and fortitude to enabling more women to become life science leaders.

  6. Engineering Proteins For Food Allergies With Ukko's Dr. Anat Binur 10/25/2022

    Anat Binur, Ph.D. is CEO and Co-Founder at Ukko, where she's leading an effort to create new allergy therapeutics by engineering the proteins that induce immune response in people who suffer from food allergies. The effort at Ukko is deeply rooted in computational biology. The company leverages artificial intelligence to analyze how the allergen proteins interact with patients' blood in an effort to determine the specific attributes of the proteins that trigger immune response. Then, it applies a unique combination of compute power and biology to identify and understand the changes it wants to engineer and predict the best possible designs. Learn how Ukko is fostering a culture of IT and biology collaboration and what lured this dynamic entrepreneur into biopharma on this episode of the Business of Biotech.

  7. Celyad CEO Filippo Petti On In-House Allogeneic Cell Therapy Manufacturing 2/8/2021

    Join Matt Pillar and Erin Harris as we catch up with Celyad Oncology chief Filippo Petti on his company's differentiated approach to the discovery and development of allogeneic CAR-T cell therapy candidates for the treatment of cancer. Petti shares the technology and how the company intends to scale in-house manufacturing in its Belgium-based manufacturing facility.

  8. BoB@JPM: Self-Replicating RNA With Elixirgen's Akihiro Ko 3/5/2023

    Elixirgen Therapeutics CEO Akihiro Ko joins the Business of Biotech for the final episode in our special series recorded at JPM Week in San Francisco. Life Science Leader Chief Editor Ben Comer joined us for the conversation. We dive deep into Elixirgen's unique, temperature-controlled in-vivo gene expression technology designed to address common cell therapy administration challenges and unwanted, off-target immungenicity effects. Ko also shares progress on the company's ex-vivo candidate EXG-34217, an autologous cell therapy for telomere biology disorders, offers his take on the ever-crowded RNA therapeutics space and how the company is separating itself from the crowd, and much more!

  9. Gene Therapies For Ocular Disease With SparingVision's Stéphane Boissel 3/28/2022

    Since assuming the President and CEO role at SparingVision in August 2020, Stéphane Boissel has been making big moves in the arenas of talent acquisition and IP expansion. Those efforts are securing the company's development of a number of genomic medicines to address inherited retinal disease. On this episode of the Business of Biotech, Boissel shares the company'S foundation story and the role venture philanthropy played in it, his strategy for attracting and retaining big-league talent, and the why behind his vigorous allegiance to internal development.

  10. Executing A Product Pivot With Vir's Mark Eisner, MD 5/7/2025

    On this week's episode of the Business of Biotech, Dr. Mark Eisner, EVP and Chief Medical Officer at Vir Biotechnology, talks about the company's post-COVID pivot into infectious diseases (Hepatitis Delta and Hepatitis B) and oncology (solid tumors), how he reprioritized the company's development candidates and assimilated Sanofi's acquired T cell engager platform, and his own transition from healthcare provider to clinical research.